CD36 is a broadly expressed transmembrane glycoprotein capable of many functions, including those carried out by scavenger receptors and others, such as adhesion ligand internalization, fatty acid transport and cell signaling. Previous work in our lab demonstrated an important role for CD36 in atherogenesis: absence of CD36 in the ApoE null background resulted in a 70 percent inhibition of aortic tree lesions. In this application, we will determine the mechanism of atheroprotection afforded by CD36 deficiency by characterizing the role of CD36 in lesion progression. and in models of atherogenesis in which insulin resistance plays a role. We hypothesize that continued progression of lesions may be due to uptake of more extensively oxidized LDL by SR-Al/Il, and we will test this hypothesis by assessment of lesion development in ApoE/CD36/SR-AI/II triple null mice. Alternatively. angiogenesis or efflux may play a role in lesion progression, and we will quantitate vessel number and investigate efflux protein expression. We will characterize the impact of the differential functions of CD36 on atherosclerosis b hematopoietic stem cell transplant and conditional cell/tissue ablation of CD36 using CRELox technology. To further investigate the mechanism of atheroprotection in the absence of CD36, we will characterize cholesterol efflux pathways in isolated macrophages from wild type and CD36 null mice, and determine the impact of prior lipid loading, and PPAR-gamma agonists. These studies will be complemented by in vivo assessment of atherosclerotic lesion development after PPAR-y treatment in LDLR/CD36 null and Apo E/CD36 null mice, and in both atherogenic backgrounds after transfer of CD36 stem cells. In this way. the contribution of macrophage CD36 to atherogenesis as compared to fat, endothelial cell and muscle CD36 can be assessed, and specific mechanisms delineated. We believe these approaches will enable us to understand the pathogenesis of foam cell and atheroma development, and lead to novel therapeutic strategies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL070083-02
Application #
6623142
Study Section
Pathology A Study Section (PTHA)
Program Officer
Wassef, Momtaz K
Project Start
2002-04-01
Project End
2006-03-31
Budget Start
2003-04-01
Budget End
2004-03-31
Support Year
2
Fiscal Year
2003
Total Cost
$423,750
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Park, Young Mi; Febbraio, Maria; Silverstein, Roy L (2009) CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. J Clin Invest 119:136-45
Kennedy, David J; Kuchibhotla, Sai D; Guy, Ella et al. (2009) Dietary cholesterol plays a role in CD36-mediated atherogenesis in LDLR-knockout mice. Arterioscler Thromb Vasc Biol 29:1481-7
Okamura, Daryl M; Pennathur, Subramaniam; Pasichnyk, Katie et al. (2009) CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. J Am Soc Nephrol 20:495-505
Kuchibhotla, Sai; Vanegas, Difernando; Kennedy, David J et al. (2008) Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II. Cardiovasc Res 78:185-96
Febbraio, Maria (2008) CD36 goes native. Arterioscler Thromb Vasc Biol 28:1209-10
Ashraf, Mohammad Z; Kar, Niladri S; Chen, Xi et al. (2008) Specific oxidized phospholipids inhibit scavenger receptor bi-mediated selective uptake of cholesteryl esters. J Biol Chem 283:10408-14
Valiyaveettil, Manojkumar; Kar, Niladri; Ashraf, Mohammad Z et al. (2008) Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI. Blood 111:1962-71
King, Kristen L; Stanley, William C; Rosca, Mariana et al. (2007) Fatty acid oxidation in cardiac and skeletal muscle mitochondria is unaffected by deletion of CD36. Arch Biochem Biophys 467:234-8
Podrez, Eugene A; Byzova, Tatiana V; Febbraio, Maria et al. (2007) Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 13:1086-95
Febbraio, Maria; Silverstein, Roy L (2007) CD36: implications in cardiovascular disease. Int J Biochem Cell Biol 39:2012-30

Showing the most recent 10 out of 16 publications